XML 17 R23.htm IDEA: XBRL DOCUMENT v3.20.1
EQUITY-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of Fair Value Assumptions The fair value of the option grants of $642,360 has been estimated with the following assumptions for the year ended December 31, 2019:
Risk-free interest rate1.61%  
Volatility103.70%  
Expected life (years)5.79
Expected dividend yield0.00%  
Summary of Stock Option Activity
The following table summarizes stock option activity for employees and non-employees for the twelve months ended December 31, 2019:
 SharesWeighted-Average
Exercise Price
Weighted-Average
Remaining
Contractual
Term (in years)
Aggregate
Intrinsic
Value
Outstanding at December 31, 2018—  $—  —  $—  
Granted101,082  8.00  
Options from Flex Pharma65,151  75.42  
Exercised—  —  
Forfeited—  —  
Expired—  —  
Outstanding at December 31, 2019166,233  $34.42  6.53$—  
Exercisable at December 31, 201984,321  $60.09  3.45$—